Shopping Cart
Remove All
Your shopping cart is currently empty
Petosemtamab (Alias: MCLA 158)
Catalog No. T76890 Copy Product Info
🥰Excellent
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).
Petosemtamab
Copy Product Info🥰Excellent
Catalog No. T76890
Alias MCLA 158
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).
Petosemtamab
Cas No. 2213450-26-9
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $355 | In Stock | In Stock | |
| 5 mg | $928 | In Stock | In Stock | |
| 10 mg | $1,490 | Inquiry | Inquiry |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC). |
| Targets&IC50 | LGR5:0.85 nM (Kd), EGFR:0.22 nM (Kd) |
| In vitro | Treatment with MCLA-158(Petosemtamab) (1 µg/mL; 24 or 72 hours) induces the degradation of EGFR in EGFR+/LGR5+ colorectal cancer organoids[2]. |
| In vivo | Treatment with MCLA-158(Petosemtamab) (25 mg/kg/week, intravenous injection, for 6 weeks) leads to tumor regression in esophageal squamous cell carcinoma, gastric adenocarcinoma, and head and neck PDX models[2]. |
| Synonyms | MCLA 158 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | LGR5 & EGFR |
| Molecular Weight | 145.97 kDa |
| Cas No. | 2213450-26-9 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Petosemtamab | purchase Petosemtamab | Petosemtamab cost | order Petosemtamab | Petosemtamab in vivo | Petosemtamab in vitro | Petosemtamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.